Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)
Condition: Healthy Volunteers
Intervention: Vonoprazan; Esomeprazole; Rabeprazole sodium
Intervention description: Vonoprazan tablets; Esomeprazole capsules; Rabeprazole sodium tablets
Intervention MeSH terms: Esomeprazole; Rabeprazole
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Enrollment: 20.0
Sex: Male
Minimum age: 20 Years
Maximum age: 45 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      The purpose of this study is to investigate the acid-inhibitory effect of multiple oral doses
      of Vonoprazan (TAK-438) and the relative effect of vonoprazan versus two controls
      (esomeprazole and rabeprazole sodium) in healthy Japanese adult male participants with the
      CYP2C19 extensive metabolizer (EM) genotype.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Is a healthy Japanese adult male volunteer.

          2. Is aged 20 to 45 years, inclusive, at the time of informed consent.

          3. Has been confirmed at CYP2C19 genotyping as an Extensive Metabolizer [EM
             (*1/*1,*1/*2,*1/*3)].

          4. Capable of understanding and complying with the protocol requirements.

          5. The participant signs and dates a written informed consent form prior to the
             initiation of any study procedures.

          6. Weighs 50 kg or more and has body mass index (BMI) of 18.5 or more and less than 25.0
             kg/m^2 at Screening or admission (Day -3).

          7. H. pylori-negative at Screening.

        Exclusion Criteria:

          1. Has undergone resection of the upper gastrointestinal tract or vagotomy.

          2. Was determined to have hypoacidity or anacidity.

          3. Has a present or past history of acid-related disease (reflux esophagitis, gastric
             ulcer, duodenal ulcer, non-erosive gastroesophageal reflux, Barrett's esophagus,
             Zollinger-Ellison syndrome, etc.).

          4. Has undergone eradication of H. pylori within 6 months prior to the start of the study
             drug administration.

          5. Has uncontrolled, clinically significant neurologic, cardiovascular, pulmonary,
             hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other
             abnormalities which may impact the ability of the subject to participate or
             potentially confound the study results.

          6. Has a known hypersensitivities or allergies to drugs or food.

          7. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol
             abuse within 5 years prior to the start of the study drug administration.

          8. Has poor peripheral venous access.

          9. Had 200 mL or more of whole blood drawn within 4 weeks (28 days) prior to the start of
             the study drug administration or 400 mL or more of whole blood drawn within 12 weeks
             (84 days) prior to the start of the study drug administration.

         10. Had a total volume of 800 mL or more of whole blood drawn within 52 weeks (364 days)
             prior to the start of the study drug administration.

         11. Has undergone blood component draw within 2 weeks (14 days) prior to the start of the
             study drug administration.

         12. Requires treatment with any of the excluded medications specified in the study or
             requires nutrition with any vitamin supplements or foods prohibited in the study.

         13. Has received study medication within 16 weeks (112 days) prior to the start of the
             study drug administration.

         14. Has received vonoprazan (TAK-438) in the past.

         15. Has a history of cancer.

         16. Has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus
             (HCV) antibody, human immunodeficiency virus (HIV) antibody/antigen or serological
             reaction for syphilis at Screening.

         17. Has a Screening or admission (Day -3) abnormal clinically significant
             electrocardiogram (ECG).

         18. Has abnormal Screening or admission (Day -3) laboratory values that suggest a
             clinically significant underlying disease or subject with the following lab
             abnormalities: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >
             twice the upper limit of the normal range.

         19. Is an immediate family member, study site employee, or in a dependent relationship
             with a study site employee who is involved in the conduct of this study (e.g., spouse,
             parent, child, sibling) or may consent under duress.

         20. Participant who, in the opinion of the investigator or sub-investigator, is unlikely
             to comply with the protocol or is unsuitable for any other reasons.